BlackLine Inc <BL.O>: Raymond James Cuts Target Price To $45 From $50
BL•Related News
Street View: Growth drugs lift Pfizer outlook, but execution remains key
PFE•
Bristol Myers drops after Reuters reports no ongoing AstraZeneca deal talks
BMY•
Journey Medical to report Q2 2026 results, host conference call
DERM•
Gerdau advances Dona Francisca Energética deal, lifts Brazil self-generated power above 50%
GGB•
W.W. Grainger, Inc. <GWW.N>: Oppenheimer Raises Target Price to $1375 from $1350
GWW•